Great Lakes Advisors LLC Makes New Investment in CVS Health Corporation $CVS

Key Points

• Great Lakes Advisors acquired 98,261 CVS shares in the second quarter, valued at approximately $10.2 million. Other institutions also initiated positions, with institutional investors collectively owning 80.66% of the company.
• CVS reported quarterly EPS of $2.58, beating estimates of $1.87, while revenue rose 7.3% year over year to $106.1 billion. The company raised its fiscal 2026 adjusted operating-income outlook, supporting its recovery narrative.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $106.75, while CVS continues to pay a quarterly dividend of $0.665 per share, representing a 2.8% annualized yield.

Great Lakes Advisors LLC acquired a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 98,261 shares of the pharmacy operator's stock, valued at approximately $10,165,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Compass Wealth Management LLC purchased a new position in CVS Health in the 2nd quarter worth $397,000. Danske Bank A S bought a new stake in CVS Health in the second quarter worth $92,122,000. Diversify Advisory Services LLC purchased a new stake in CVS Health during the second quarter valued at about $3,609,000. Gables Capital Management Inc. bought a new position in shares of CVS Health during the second quarter valued at about $52,000. Finally, Wealthfront Advisers LLC purchased a new position in shares of CVS Health in the second quarter worth about $19,660,000. Institutional investors own 80.66% of the company's stock.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported strong second-quarter results, with earnings per share rising more than 40% year over year as profitability in its Health Care Benefits segment improved. The company also raised its 2026 adjusted operating income outlook, reinforcing the recovery story. CVS Q2 EPS Gains From Improved Health Care Benefits Profitability
• Positive Sentiment: CVS appointed Teresa Heitsenrether, JPMorgan’s data and analytics chief, to its board. Her technology, analytics and operating experience could support CVS’s artificial-intelligence and data initiatives, potentially improving efficiency and decision-making across its businesses. CVS adds JPMorgan data executive to board amid AI push
• Positive Sentiment: Brokerages assigned CVS an average “Moderate Buy” rating, reflecting improved earnings momentum and optimism about Aetna’s performance. CVS Health Given Average Rating of Moderate Buy

CVS Health Stock Up 0.9%

Shares of NYSE CVS opened at $94.87 on Wednesday. The firm has a fifty day simple moving average of $102.41 and a two-hundred day simple moving average of $88.56. CVS Health Corporation has a 12 month low of $69.51 and a 12 month high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $121.33 billion, a PE ratio of 25.10, a price-to-earnings-growth ratio of 0.93 and a beta of 0.61.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. During the same quarter in the previous year, the company earned $1.81 earnings per share. CVS Health's quarterly revenue was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities analysts expect that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. CVS Health's dividend payout ratio is 70.37%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft boosted their target price on CVS Health from $88.00 to $92.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. Morgan Stanley lifted their price target on CVS Health from $106.00 to $111.00 and gave the stock an "overweight" rating in a research note on Thursday, June 4th. UBS Group boosted their price objective on CVS Health from $122.00 to $126.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Truist Financial increased their price objective on CVS Health from $108.00 to $118.00 and gave the company a "buy" rating in a research note on Tuesday, July 14th. Finally, Bank of America raised their target price on shares of CVS Health from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Monday, June 22nd. Twenty-two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, CVS Health has an average rating of "Moderate Buy" and a consensus price target of $106.75.

Insider Activity

In other news, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the completion of the transaction, the director owned 4,824,799 shares of the company's stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.85% of the company's stock.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source